Bard Geesaman Net Worth

Bard Geesaman biography

Dr. Bard J. Geesaman M.D. Ph.D. serves as Independent Director of the Company. Dr. Geesaman joined our Board of Directors in 2004. Dr. Geesaman was at MPM Capital for over a decade before leaving in December 2018. He has broad experience investing, operating and facilitating business development globally, including in Japan, China and Israel. Prior to joining MPM, Dr. Geesaman founded Catalyst Medical Solutions, a medical documentation and billing eHealth company in Boston where he served as the Chief Technology Officer through the company’s acquisition. After Catalyst, Dr. Geesaman joined Centagenetix, an MPM-founded company exploring the genetics of successful aging. In 2006, Dr. Geesaman joined MPM as a Venture Partner with a major focus on founding Solasia Pharmaceuticals, based in Tokyo, Japan which listed on the Tokyo Mothers exchange in March 2017. Dr. Geesaman is also the co-founder and a board member of MPM healthcare IT startup TriNetX (big data analytics for clinical trials). Dr. Geesaman is passionate about innovation in health care, and in 2008 took a two-year sabbatical from MPM to do non-profit work in Los Angeles at the X-Prize Foundation, where he worked on alternative models for motivating life sciences innovation. Dr. Geesaman became board certified in Internal Medicine in 2000, after completing a Clinical Fellowship at the Massachusetts General Hospital. He received his Ph.D. from MIT, an M.D. from Harvard Medical School and a B.S. from University of California, Berkeley.

What is the salary of Bard Geesaman?

As the Independent Director of Chiasma Inc, the total compensation of Bard Geesaman at Chiasma Inc is $113,130. There are 12 executives at Chiasma Inc getting paid more, with Raj Kannan having the highest compensation of $6,413,280.

How old is Bard Geesaman?

Bard Geesaman is 52, he's been the Independent Director of Chiasma Inc since 2004. There are 9 older and 3 younger executives at Chiasma Inc. The oldest executive at Chiasma Inc is John Scarlett, 69, who is the Independent Director.

What's Bard Geesaman's mailing address?

Bard's mailing address filed with the SEC is C/O CHIASMA, INC., 140 KENDRICK STREET, BUILDING C EAST, NEEDHAM, MA, 02494.

Insiders trading at Chiasma Inc

Over the last 9 years, insiders at Chiasma Inc have traded over $0 worth of Chiasma Inc stock and bought 324,855 units worth $2,372,906 . The most active insiders traders include Llp Abingworth, Ansbert Gadicke und John F Thero. On average, Chiasma Inc executives and independent directors trade stock every 85 days with the average trade being worth of $94,895. The most recent stock trade was executed by Roni Mamluk on 9 February 2021, trading 27,981 units of CHMA stock currently worth $51,765.

What does Chiasma Inc do?

Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.

Chiasma Inc executives and stock owners

Chiasma Inc executives and other stock owners filed with the SEC include:

• Raj Kannan,
  Chief Executive Officer, Director
• anand Varadan,
  Executive Vice President, Chief Commercial Officer
• Mark Fitzpatrick,
  President, Chief Financial Officer
• William Ludlam,
  Senior Vice President - Clinical Development and Medical Affairs
• Lee Giguere,
  Vice President, General Counsel, Secretary
• Drew Enamait,
  Vice President, Finance and Administration, Principal Accounting Officer
• Roni Mamluk,
  Director
• David Stack,
  Independent Chairman of the Board
• Scott Minick,
  Independent Director
• John Scarlett,
  Independent Director
• John Thero,
  Independent Director
• Todd Foley,
  Independent Director
• Bard Geesaman,
  Independent Director
• Ashley Robinson,
  IR Contact Officer
• Health Ventures Lp Wertheim...,
  
• Bio Ventures Iv Qp Lpevnin ...,
  
• Ansbert Gadicke,
  Director
• Mark Leuchtenberger,
  CEO, President
• James R Tobin,
  Director
• Tara Mc Carthy,
  General Counsel and Secretary
• Vincent J Miles,
  Director
• Llp Abingworth,
  10% owner
• John Brendan Doyle,
  Chief Financial Officer
• Capital, L.P. Stonepine,
  10% owner